Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer
Edward M. Kennedy(Oncor (United States)), Lorena Lerner(Oncor (United States))
Cited by 4
Related Papers
STAT3-dependent enhanceosome assembly and disassembly: synergy with GR for full transcriptional increase of the α2-macroglobulin gene
|Genes & Development|2003|117
Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer
|Nature Communications|2022|40